NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29 2024 - 7:05AM
Business Wire
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, will attend the Morgan Stanley 22nd
Annual Global Healthcare Conference. Chris Smith, Chief Executive
Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone,
Chief Commercial Officer, will participate in an in-person fireside
chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York
City.
The presentation will be webcast live and accessible online via
this link. A replay will be available on the Investor Relations
section of the Company’s website at ir.neogenomics.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus for physicians to help them diagnose
and treat cancer. The Company’s Advanced Diagnostic Division also
serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
Forward-Looking Statements
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “plan,” “could,” “would,”
“may,” “will,” “believe,” “estimate,” “forecast,” “goal,”
“project,” “guidance,” “plan,” “potential” and other words of
similar meaning, although not all forward-looking statements
include these words. This press release includes forward-looking
statements. These forward-looking statements address various
matters, including statements regarding improving operational
efficiency, returning to profitable growth and its ongoing
executive recruitment process. Each forward-looking statement
contained in this press release is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, the Company's ability to
identify and implement appropriate financial and operational
initiatives to improve performance, to identify and recruit
executive candidates, to continue gaining new customers, offer new
types of tests, integrate its acquisitions and otherwise implement
its business plan, and the risks identified under the heading "Risk
Factors" contained in the Company's Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and the Company's other filings with
the Securities and Exchange Commission.
We caution investors not to place undue reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this document (unless another date is
indicated), and we undertake no obligation to update or revise any
of these statements. Our business is subject to substantial risks
and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240829956644/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Oct 2024 to Nov 2024
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Nov 2023 to Nov 2024